Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million,...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned su...
Upgrades
Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently report...
Truist Securities analyst Gregory Fraser downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Hold and lowers the price targe...
Ladenburg Thalmann analyst Matthew Kaplan downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral.
Raymond James analyst Elliot Wilbur downgrades Antares Pharma (NASDAQ:ATRS) from Strong Buy to Market Perform.
HC Wainwright & Co. analyst Oren Livnat downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral and announces $5.6 p...
Piper Sandler analyst David Amsellem downgrades Antares Pharma (NASDAQ:ATRS) from Overweight to Neutral and lowers the price...
